(Parte 2 de 3)

Revista Brasileira de Cancerologia 2007; 53(3): 335-343

Grivicich I, Regner A, Rocha AB lesado. A compreensão dos mecanismos e das alterações nos componentes das vias apoptóticas e sua correlação com a ocorrência do câncer são importantes para o desenvolvimento de novas terapias e métodos de prevenção do câncer.

1.Meier P, Finch A, Evan G. Apoptosis in development. Nature. 2000;407:796-801.

2.Yu SP, Choi DW. Ions, cell volume, and apoptosis. Proc Natl Acad Sci USA. 2000;97:9360-362.

3.Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-76.

4.Okada H, Mak TW. Pathways of apoptotic and nonapoptotic death in tumour cells. Nat Rev Cancer. 2004;4:592-603.

5.Dimri GP. What has senescence got to do with cancer? Cancer Cell. 2005;7:505-12.

6.Castedo M, Perfettini JL, Roumier T, Andreau K, Medema

R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825-837.

7.Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist. 2006;1:342-57.

8.Danial N, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205-19.

9.Lum J, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol. 2005;6:439-48.

10.Kelekar A. Autophagy. Ann NY Acad Sci. 2005;1066:259-71.

1.Ziegler U, Groscurth P. Morphological features of cell death. News Physiol Sci. 2004;19:124-28.

12.Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev. 2006;20:1-15.

13.Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005;8:7-12.

14.Mooi WJ, Peeper DS. Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med. 2006;355:1037-1046.

15.Lockshin RA, Williams CM. Programmed cell death I.

Endocrine potentiation of the breakdown of the intersegmental muscles of silkmonths. J Insect Physiol. 1964;10:643-49.

16.Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;6:239-57.

17.Ranganath RM, Nagashree NR. Role of programmed cell death in development. Int Rev Cytol. 2001;202:159-242.

18.Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res. 2000;45:528-37.

19.Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000;407:810-16.

20.Liu QA, Hengartner MO. The molecular mechanism of programmed cell death in C. elegans. Ann N Y Acad Sci. 1999;887:92-104.

21.Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;2:299-306.

2.Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol. 2003;15:725-31.

23.Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem Rev. 2002;102:4489-500.

24.Rupnarain C, Dlamini Z, Naicker S, Bhoola K. Colon cancer: genetics and apoptotic events. Biol Chem. 2004;385:449-64.

25.Schuler M, Maurer U, Goldstein JC. p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ. 2003;10:451-60.

26.Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39:615-47.

27.Vander Heiden MGV, Thompson CB. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol. 1999;1:E209-16.

28.Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta. 2004;1644:83-94.

29.Bronner MO, Culin C, Reed JC, Furth E. The bcl-2 proto-oncogene and the gastrointestinal tumor progression model. Am J Pathol. 1995;146:20-26.

30.Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris

M, Lock RB. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ. 2000;7:102-1.

31.Deveraux QL, Reed JC. IAP family proteins- suppressors of apoptosis. Genes Dev. 1999;13:239-52.

32.Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9:459-70.

3.Seshagiri S, Miller LK. Baculovirus inhibitors of apoptosis

(IAPs) block activation of Sf-caspase-1. Proc Natl Acad Sci USA. 1997;94:13606-611.

34.Verhagen AM, Ekret PG, Pakusch M, Silke J, Connolly

LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43-53.

35.Du C, Fang M, Li Y, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation during apoptosis. Cell. 2000;102:3-42.

36.Chai J, Du C, Wu JW, Kyrin S, Wang X, Shi Y. Structural and Biochemical basis of apoptotic activation by smac/ DIABLO. Nature. 2000;406:855-62.

37.Badley AD, Pilon A, Landay A, Lynch DH. Mechanisms

Revista Brasileira de Cancerologia 2007; 53(3): 335-343

Apoptose of HIV-associated lymphocyte apoptosis. Blood. 2000;96:2951-964.

38.Ferreira CG, Epping M, Kruyt FAE, Giaccone G.

Apoptosis: target of cancer therapy. Clin Cancer Res. 2002;8:20-34.

39.Li F, Ling X. Survivin study: an update of "what is the next wave?" J Cell Physiol. 2006;208:476-86.

40.Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem. 1998;273:1-4.

(Parte 2 de 3)